VeriChip Corporation and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, announced today they will host an event for the medical, patient and investor communities on October 22, 2009, in New York to unveil details of their virus triage detection system for the H1N1 virus and Phase II development of an in vivo glucose-sensing RFID microchip.
124667
VeriChip Corporation and RECEPTORS LLC to unveil development
22122
Microfluidics rebrands MRT nanoparticle creation technology as PureNano platform
556
Merck, Serum partner to develop pneumococcal conjugate vaccine
168068
AGROPROMPROEKT doubles design and exploration work in 2007
126233
Astex achieves milestones in drug discovery collaboration
80251
PivotPoint Innovation enables insider access to breakthrough innovations
9645
Life sciences industry hangs out help wanted signs
122540
Sorin Group and Orange Business Services launch a remote monitoring solution for patients with implanted cardiac devices in Europe
67144
Qiagen launches ScreenGel software for QIAxcel® multicapillary gel electrophoresis systems
46057
NAVTEQ selected by the Center for disease Control and Prevention (CDC)
63919
Angiogenesis inhibitor formulated through nanotechnology shows promising anticancer results
27383
World outlook for products incorporating nanotechnology
134688
Avesthagen scouting for partners for bioactive ingredients
151825
Toward stem cell pharmacies
27570
Smartrend's candlestick scanner detects bullish engulfing pattern for Viropharma (vphm)
117521
New molecule that can travel into cells, deliver genetic cargo, and packs a beacon
156830
Boston Scientific PREVAIL trial meets two out of three co-primary endpoints